A detailed history of Royce & Associates LP transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 59,009 shares of TBPH stock, worth $561,765. This represents 0.0% of its overall portfolio holdings.

Number of Shares
59,009
Previous 59,009 -0.0%
Holding current value
$561,765
Previous $500,000 5.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 08, 2021

SELL
$14.89 - $20.16 $510,592 - $691,306
-34,291 Reduced 36.75%
59,009 $1.05 Million
Q2 2017

Aug 07, 2017

BUY
N/A
93,300
93,300 $3.72 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $636M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.